Pharmaceutical Technology

APRIL 25, 2024

A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.

52

52

World of DTC Marketing

NOVEMBER 3, 2020

has also seen reversals in health improvements since 2010, partly due to increasing rates of obesity, high blood pressure, and high blood sugar. . Obesity, lack of exercise, and too much salt are all contributing to a myriad of health issues that are going to drive up healthcare costs. is lower than in other high-income countries.

Insurance 190

Insurance Healthcare Healthcare Physicians 190

Pharmaceutical Technology

JANUARY 17, 2023

Bimagrumab is of interest in the obesity space as it is a first-in-class therapy for obesity. Bimagrumab is an activin receptor type 2B (ACVR2B or EC 2.7.11.30) antagonist that offers a unique mechanism of action within the obesity market. Mounjaro is anticipated to launch in the US later this year or by early 2024.

Marketing 52

Marketing Patients Safety Pharmaceutical 52

Celeritas

NOVEMBER 7, 2022

Automated feeders may use Variable-Rate Technology to regulate intake to reduce obesity and meet nutritional standards. In conjunction with tags, facial expression readers, or electromagnetic RFID tags, drones can monitor the health indicators of individual herd members. Satellite-based monitoring. Mounted Devices.

Networking 52

Networking Pharmaceutical products Management Transportation 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. were obese, and 9.2%

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. were obese, and 9.2%

Medical 98

Medical Manufacturing Insurance Side effects 98

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.

Healthcare 40

Healthcare Healthcare Marketing Pharma 40